Clinical Trials on Losartan
Total 2 results
-
Mostafa Hassanein, MscCompletedSport Injury | Muscle Injury | PRP | Losartan
-
Mansoura UniversityCompletedUropathy | Losartan Adverse Reaction | Uropathy ObstructiveEgypt
Sponsors and Collaborators
- Maternity Foundation
- Afecta Pharmaceuticals
- Excellence Center at Linköping - Lund in Information Technology (ELLIIT)
- SOFTWARE IMAGINATION & VISION SRL
- Novacea
- Foundation Child Care - FAN
- Center for Sport Studies, Rey Juan Carlos University
- Hervé Quintard
- Leandro P. Rizzuto Foundation
- SpliSense Ltd.
- Todd Moyerbrailean DO FACOG
- Peter J Pugh
- Vascular Neurology of Southern California Inc.
- Neonatal and Paediatric Intensive Care Unit, Children's Hospital St. Gallen, Switzerland
- KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre Balgaum, India
- Guangzhou Burning Rock Bioengineering Co., Ltd
- Fundacion Rioja Salud
- Vaxcyte, Inc.
- Intensive Care Unit Pasteur Hospital
- Blessing Corporate Services, Inc
- View Full List
Medical Conditions
- SARS-CoV-2 Infection, COVID-19
- Use of Prescription Medications
- Acute Liver Injury, Drug Induced
- Distalization by Miniscrews
- Endometrial Receptivity Failure
- Cryoglobulinaemic Glomerulonephritis
- Intra-operative Anesthesia
- - Mild and Moderate Presbycusis (20 to 50 dB Average Hearing Loss at 500, 1000, 2000 Hz and 4000 Hz)
- Localized Resectable Adult Primary Liver Cancer
- Quality of Life in Schizophrenia
- Non-technical Skills (NTS)
- Upper GI Tract Carcinoma
- Other Obstetric Trauma OS
- Vision Loss
- To Evaluate the User Experience With a Closed Loop System
- TP53 R249S
- Sellar and Suprasellar Masses
- Subclinical Spinal Pain
- Extra Spermatozoa
- Tuberculosis (TB)
- View Full List
Drug Interventions
- Antithymocyte globulin (Rabbit)
- Xenon
- Octreotide
- AZD7325
- Luliconazole Cream 1% - 2 wks
- Leucovorin
- Ascorbic Acid
- RBS2418
- AMT-101 (oral)
- Trastuzumab
- Tenecteplase
- GW-1000-02
- Enfuvirtide-intensified HAART
- Bevacizumab standard of care
- Topical Solution
- Fluvastatin
- Prolonged release (PR) OROS methylphenidate 72 mg
- Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
- BMS-770767
- Standard of care
- View Full List
CROs by country
- Contract Research Organizations in Belgium
- Contract Research Organizations in Czech Republic
- Contract Research Organizations in Ghana
- Contract Research Organizations in Italy
- Contract Research Organizations in Jamaica
- Contract Research Organizations in Kosovo
- Contract Research Organizations in Lithuania
- Contract Research Organizations in Malta
- Contract Research Organizations in Paraguay
- Contract Research Organizations in Peru
- Contract Research Organizations in Serbia
- Contract Research Organizations in Suriname
- Contract Research Organizations in Turkmenistan
- CRO list by country